3 medical AI systems clear regulatory hurdles

Dave Pearson | | Health Exec | Economics
hurdles.jpg
Photo by Interactive Sports via Unsplash

The last two weeks saw market clearances granted in Europe for AI-based software focused on remote patient monitoring, prostate oncology and real-time guidance of coronary stenting.

Company announcements:

Biobeat’s AI-powered remote patient monitoring platform receives a full CE mark (May 4)

Exini Diagnostics receives CE mark clearance for AI-powered quantitative assessment of prostate-specific membrane antigen (May 3)

Abbott’s new coronary imaging platform powered by artificial intelligence launches in Europe (April 26)

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

Cardiologist sues health system over gender discrimination, unequal pay and hostile treatment
FTC, DOJ and HHS release report warning of private equity consolidation in healthcare
Q&A: Vulnerable patients hit hardest by anesthesia reimbursement cuts
Momentum continues for renal denervation as CMS considers national Medicare coverage
Johnson & Johnson buys depression drug and its manufacturer for $15B
UnitedHealth, Amedisys ask federal judge to dismiss DOJ lawsuit blocking $3.3B merger

Around the web

Cardiovascular Business
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

AI in Healthcare
4 ways HHS plans to help shape a national strategy for healthcare AI

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.

Cardiovascular Business
FDA announces recall after Philips heart monitor software failed to send alerts—multiple deaths reported

Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries.